In June 2000, the leaders of the public Human Genome Project and of Celera Genomics appeared together at the White House to announce a working draft of the human genome. The announcement promised a flood of biological data. It said much less about who would make sense of it.
That same year in Bangalore, a group of computer scientists with deep roots at the Indian Institute of Science founded a company to work on exactly that question. It was called Strand Genomics. Company and industry records name Ramesh Hariharan, Viswanathan Vinay, Swami Manohar and S. Seshadri among its founders. Vijay Chandru — an IISc computer scientist who had earlier helped develop the Simputer, a low-cost handheld computer — served as chairman and chief executive through much of its growth.
Their expertise was not biology. It was algorithms: how to search, cluster, model and visualise very large datasets. The bet was that biology was becoming a data problem, and that people who were good at data problems could contribute to it.
The bet was right. What makes Strand's story worth telling is how much more than being right it took.

A capability is not a product.
A research capability answers the question “what can we do?” A company has to answer a different one: what will someone pay for, repeatedly, and why from us? For a team of algorithm specialists, the first answer was software. Strand built a data-mining and visualisation platform called Avadis, designed so that one analytical engine could be adapted to different scientific domains — gene expression first, and later next-generation sequencing, pre-clinical research and chemistry.
The platform choice mattered. Bioinformatics in the early 2000s was crowded with point tools, each built for one kind of experiment. A reusable engine let a small team serve several markets without starting from scratch each time.
A research capability answers “what can we do?” A company has to answer “what will someone pay for, repeatedly — and why from us?”
Recognition followed. Avadis received a Frost & Sullivan technology award in 2005, and the World Economic Forum named Strand a Technology Pioneer. But recognition is not revenue. Life-science software is sold to laboratories that already have tools, habits and procurement processes. A young company from Bangalore had to persuade them to change.
Borrowing a channel.
Strand's answer was partnership. It had already been working with Stratagene, a US life-sciences company. When Agilent Technologies acquired Stratagene in 2007, the relationship grew: in August that year, Agilent announced that Strand would develop GeneSpring, a widely used gene-expression analysis package Agilent had acquired with Silicon Genetics in 2004. Announcing the deal, Chandru said Strand's “proven Avadis platform will power the market-leading GeneSpring products.”
The arrangement solved a distribution problem Strand could not easily solve alone. Agilent brought a global brand, a sales force and an installed base of instruments and customers. Strand brought the engineering. The trade-off was visibility: much of Strand's best-known work reached scientists under another company's name. The agreement was renewed in 2010 to extend GeneSpring across several kinds of “omics” data.
By the company's account, Strand reached profitability in 2007, and its software came to be used by around 1,400 research institutions worldwide under the GeneSpring and Avadis names. These are company figures, but they describe something real: research-grade expertise had become a dependable, paid-for product with an international customer base.
A ceiling in the market.
Then came a harder question. Discussing a $10 million Series B round raised to build clinical-genomics infrastructure, Chandru told the trade publication GenomeWeb that the existing tools-and-consulting business was “sustaining and self sufficient.” He also said the research market for genomics analysis software was “modest at best.”
That is a familiar ceiling for science-based companies. A product can be excellent and profitable and still be limited by the size of its market. Strand's response was to move toward the place where genomic data would be used to make decisions: the clinic.
Sequencing costs had fallen dramatically through the late 2000s, making it plausible to test patients' genes for cancer and inherited disease as a matter of routine. Interpreting those results — deciding which of thousands of genetic variants matter for a particular patient — was exactly the kind of problem Strand's software and scientists had been working on in research settings.
A different company around the same science.
Moving into diagnostics was not an extension of the software business. In practical terms, it meant building a new one. A clinical genomics service needs a wet laboratory, sample logistics, trained laboratory staff, turnaround commitments, relationships with oncologists and geneticists, reports a clinician can act on, and quality systems that can withstand outside inspection.
From research scientists to clinicians, hospitals and, ultimately, patients.
From code and servers to sequencers, samples and a wet lab.
From a flawed analysis to a decision about someone's treatment.
From product reviews to external inspection and accreditation.
Strand began serving the Indian clinical market in 2013. It opened its own sequencing and gene-panel laboratory in Bangalore and, that December, a laboratory inside the Mazumdar-Shaw cancer centre in the city. By the company's account, it was serving more than 100 hospitals in India by the end of that year. Its offerings came to include StrandAdvantage tests for cancer and StrandOmics, a platform for interpreting genetic variants and preparing clinical reports.
Behind the reports sat a less visible asset: curated knowledge. Deciding what a variant means requires evidence from the published literature and from databases, reviewed by people who know how to weigh it. Strand describes its oncology reporting platform as the product of roughly a decade of curation and automation, and its team as including curation scientists alongside software engineers, bioinformaticians and clinical researchers.

Trust you can audit.
In clinical work, credibility has to be demonstrable to strangers. In February 2016, Strand announced that its next-generation sequencing laboratory in Bangalore had been accredited by both the College of American Pathologists (CAP) and India's National Accreditation Board for Testing and Calibration Laboratories (NABL), and described it as the first laboratory of its kind in India to hold both.
Accreditation is easy to misread. It does not certify that a given test is right for every patient, or that genomic testing will change a particular outcome. What it certifies is the laboratory: that its processes, personnel, quality management and proficiency testing meet an external standard, verified by inspection. For a company asking hospitals to rely on its results, that is not paperwork. It is part of the product.
For a company asking hospitals to rely on its results, accreditation is not paperwork. It is part of the product.
One way to read Strand's history is as a sequence of credibility, each step making the next believable to people who could not inspect the science themselves: awards for its platform, a global partner's brand on its engineering, then external accreditation of its laboratory.
Capital and ownership.
A clinical business consumes capital in a way that software does not. Strand raised money over several rounds — including the Series B for clinical infrastructure and a Series C in 2018 — from investors that included Kiran Mazumdar-Shaw. In 2021, Reliance Strategic Business Ventures, part of Reliance Industries, acquired a majority stake, and Strand became part of the Reliance group.
How to read that depends on what you think a science company is for. The acquisition returned value to early backers and gave the business access to a much larger group's resources and reach. It also closed Strand's independent chapter after about two decades. Both readings are fair. What is clear is that a capability first assembled in 2000 was still in use, and still growing, more than twenty years later.
What the journey suggests.
It is worth separating what Strand did from what one might draw from it. What Strand did is a matter of record: it built analytical software from research-grade expertise, partnered with a global company to distribute it, reported profitability, moved into clinical genomics with its own laboratories, earned external accreditation and was acquired by a larger group. What follows is our reading, not Strand's.
The same capability can be packaged many ways. Software, partner engineering, services and clinical testing all drew on related expertise. The right package changed as markets changed.
Market size shapes the company. A profitable product can still hit a ceiling. Moving past it may mean becoming a different kind of organisation.
Credibility is cumulative, and it has to be legible. Customers, partners and regulators judge what they can verify, not what the founders know.
Even data companies end up needing physical infrastructure. Clinical genomics required a wet lab, samples and trained people — capabilities no algorithm supplies.
None of this was inevitable, and survivorship colours every success story. Many capable scientific teams of the same era did not build lasting companies. The point is not that Strand's path is a template. It is that the path — every turn of it — was work beyond the science.
Research translation needs more than technical talent. It needs pathways that connect scientists to engineering teams, industry partners, customers and commercial execution — and room for a venture to change shape as it learns what the market will bear. That is the environment ARTPARK is trying to build around the researchers and startups it works with.
Scientific excellence does not automatically become a successful company. Research has to become validated offerings, trusted relationships and a business able to pay for what comes next.
- “Agilent Technologies and Strand Life Sciences Announce GeneSpring Development Agreement,” Agilent announcement via Technology Networks (2007).
- “Strand Secures $10M Series B Funding to Develop Clinical Genomics Infrastructure,” GenomeWeb.
- Strand Life Sciences press releases — CAP and NABL accreditation (February 2016); Avadis NGS renamed Strand NGS (July 2014). strand-ngs.com/press.
- Strand Life Sciences, company website — history, capabilities and team. strandls.com.
- Vijay Chandru, personal website — vijaychandru.in.
- Reliance Industries, stock-exchange disclosure on the acquisition of Strand Life Sciences (2021).
Founding-team, customer, hospital and profitability figures are as reported by the company or trade press and have not been independently audited. We welcome corrections from people who were there. ARTPARK had no involvement in the history described here.